世界の医療・医薬品産業レポート

TOP  >  作用機序別レポート  >  Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - パイプラインレビュー 2018年上半期

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - パイプラインレビュー 2018年上半期
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H1 2018

レポートタイトル Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - パイプラインレビュー 2018年上半期
出版社名 Global Markets Direct
発刊日 2018-04-10
体裁 PDF / 42 ページ
シングルユーザ価格 US$ 3,500
レポート分類 作用機序別レポート
地域 グローバル
領域 -
疾患名 -
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記の作用機序を標的とした治療薬パイプラインについての詳細な分析、該当作用機序についての包括的な情報、標的とする治療薬、および適応症、開発段階、作用機序(MoA)、投与方法(RoA)や分子タイプについての分析を提供します。
また、開発の歴史、最新のニュース、プレスリリースについても取り上げます。
さらに、開発中、開発中止プロジェクトの治療薬に関わる主要企業の概要も提供します。
また、該当作用機序の治療薬開発に関わる主要企業概要、開発中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Overview
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Companies Involved in Therapeutics Development
Leadiant Biosciences Inc
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Drug Profiles
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-2180 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-30119 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pixatimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharides to Inhibit Heparanase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharides to Inhibit Heparanase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roneparstat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Heparanase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Heparanase for Inflammatory Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Heparanase for Type 1 and Type 2 Diabetes and Age Related Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HPSE and VEGF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Dormant Products
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Discontinued Products
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Product Development Milestones
Featured News & Press Releases
Jul 21, 2014: European Patent Office Intention to Grant ‘Sulfated Oligosaccharide Derivatives’ Patent
Oct 29, 2013: PG545 Phase 1 Cancer Trial Update
Jul 09, 2013: PG545 Pre-Clinical Data in Experimental Pancreatic Cancer Models Published in Molecular Cancer Therapeutics
May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001
May 30, 2012: Progen Pharma Obtains Australian Patent For Heparan Sulfate Mimetic Compounds
Sep 20, 2011: Progen Announces Closure Of PG545 Phase Ia Clinical Trial
Oct 14, 2009: New Preclinical Data Confirms PG545 As A Promising Clinical Candidate For Cancer
Apr 14, 2008: Progen Pharmaceuticals Announces presentation of New Data on PG500 Series of Compounds at the AACR Meeting in San Diego
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Leadiant Biosciences Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
Loading....